ClinicalTrials.gg

Program

GSK4527363

A development code.

In GlaxoSmithKline's pipeline, B-cell modulator. Its studies are mostly in Lupus Erythematosus, Systemic, led by GlaxoSmithKline.

Furthest: phase 1, since Aug 26, 20241 company-led study, 1 open or runningNext primary completion: Feb 1, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 1since Aug 26, 2024Aug 26, 2024Feb 1, 2028phase 1 · NCT06576271
  • Named in GlaxoSmithKline’s own pipeline as GSK4527363, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 26, 2024First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT06576271 · 143 enrolled · United States, Argentina, Brazil and more

Ahead

  1. Feb 1, 2028Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06576271

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“B-cell modulator”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06576271Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more1Active, not recruitingFeb 1, 2028143

How it is read

Names in the registry

  • “GSK4527363”, 1 entry

Codes read as this program: GSK4527363.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.